Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM versus PREVACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM versus PREVACID.
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM vs PREVACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Esomeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase pump in gastric parietal cells, decreasing gastric acid secretion.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
One tablet (naproxen 500 mg / esomeprazole 20 mg) orally twice daily.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
None Documented
None Documented
Naproxen: ~12-17 hours (allows twice-daily dosing). Esomeprazole: ~1-1.5 hours (no accumulation).
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Naproxen: ~95% renal (as unchanged drug and conjugates), ~5% fecal. Esomeprazole: ~80% renal (as metabolites), ~20% fecal.
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor